NCT05305989View on ClinicalTrials.gov

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

June 6, 2024

Study Completion Date

June 6, 2024

Conditions
Chronic Graft-versus-host-disease
Interventions
DRUG

Belumosudil 200 mg QD

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

DRUG

Belumosudil 200 mg BID

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

DRUG

Belumosudil 400 mg QD

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Trial Locations (8)

15232

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132, Pittsburgh

63110

Washington University School of Medicine Site Number : 125, St Louis

78229

Texas Transplant Institute Site Number : 079, San Antonio

78704

South Austin Medical Center Site Number : 091, Austin

91010

City of Hope Site Number : 050, Duarte

94305

Stanford Cancer Center Site Number : 108, Stanford

98109

Fred Hutchinson Cancer Research Center Site Number : 052, Seattle

77030-4009

MD Anderson Cancer Center Site Number : 057, Houston

All Listed Sponsors
lead

Kadmon, a Sanofi Company

INDUSTRY